Odense University Hospital

STOCKHOLM, April 25, 2025 /PRNewswire/ -- RaySearch Laboratories AB (publ) announces that Odense University Hospital (OUH), which is part of the South Denmark Region, has placed an order for RayStation®*. The radiotherapy center at OUH is known for being at the forefront of automated solutions to provide high-quality care in an efficient way, including the ability to automatically generate treatment plans. With the introduction of RayStation, the clinic is now taking the next step by further developing automation to cover all aspects of the treatment planning process-from initial planning to finalized treatment plans. RayStation was chosen after an extensive evaluation of the market, where the decisive factor was to find a system that would enable OUH to continue developing new automated methods. RaySearch has had a strong focus on automation for a long time. RayStation offers several approaches for automated planning, both using machine learning techniques but also more conventional automated planning algorithms. In the upcoming version of RayStation, a new algorithm for automated optimization, which is still under development and led by Memorial Sloan Kettering Cancer Center in the US, will be included. The objective of the implementation project at Odense's radiotherapy center is to analyze the advantages of different auto-planning approaches and to clinically apply the approach that is best suited for each tumor site. Henrik Robenhagen Jensen, Chief Physicist, Odense University Hospital: "Odense University Hospital has long been dedicated to enhancing the quality of treatment planning, with a strong research focus on improving outcomes for cancer patients through state-of-the-art radiotherapy technologies. We are excited to begin our collaboration with RaySearch, which we see as a significant step forward. This partnership holds great promise for advancing automated treatment planning, with a clear emphasis on quality, efficiency, and the optimal use of clinical resources." Johan Löf, founder and CEO, RaySearch: "We have long been committed to increasing the degree of automation in RayStation. We are therefore particularly pleased that Odense University Hospital has chosen RayStation primarily based on this functionality. I am convinced that we will meet the center's requirements for automation and look forward to their feedback and a fruitful cooperation." The order value is DKK 10.5 million (approximately SEK 15.4 million), excluding service contract, of which the majority will be recognized as revenue in the first quarter of 2025. * Subject to regulatory clearance in some markets. For more information, please contact: Johan Löf, founder and CEO, RaySearch Laboratories AB (publ) Telephone: +46 (0) 8 510 530 00 [email protected]  Learn more about us on: LinkedIn YouTube This information was brought to you by Cision The following files are available for download: SOURCE RaySearch Laboratories WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

German drugmaker Boehringer Ingelheim didn’t share any data behind the top-line result, instead promising that the efficacy and safety findings would be unveiled in the second quarter.\n Boehringer Ingelheim has cemented the potential of its idiopathic pulmonary fibrosis (IPF) drug with a second phase 3 win in a related lung disease leading the drugmaker to expand the indications it will seek FDA approval for.The FIBRONEER-ILD trial saw 1,178 patients with progressive pulmonary fibrosis (PPF) receive either a 9 mg or 18 mg dose of the PDE4B inhibitor nerandomilast or placebo twice a day for 52 weeks. The study hit its primary endpoint of demonstrating an absolute change from baseline in forced vital capacity—a measure of the volume of air that a patient can breathe out—Boehringer said in a Feb. 10 release.The German drugmaker didn’t share any data behind the top-line result, instead promising that the efficacy and safety findings would be unveiled in the second quarter.“Initial data readouts of the FIBRONEER trials support a generally consistent safety and tolerability profile when compared to the phase 2 IPF study, with overall adverse events comparable to those seen in the placebo group,” the company said.Armed with the latest results, Boehringer said it will request that FDA and global regulators approve nerandomilast as a treatment for PPF, a type of interstitial lung disease. The company has already said it will seek approval for nerandomilast in IPF after proclaiming a win in a phase 3 trial for that lung disease in September 2024. Again, the company opted to hold back any concrete data from that trial for later in this year.When it comes to managing IPF, physicians already have Boehringer’s Ofev and Roche’s Esbriet. However, those drugs only slow the progression of fibrosis, while attempts to produce molecules that further slow, or ideally stop, progression have failed to prove their worth.By targeting phosphodiesterase 4B (PDE4B), nerandomilast is meant to have a mechanistic advantage over the incumbent products. Targeting PDE4 drives anti-inflammatory and antifibrotic effects, but attempts to develop oral inhibitors of the enzyme in respiratory diseases have been hindered by class-related systemic adverse events such as diarrhea and headaches.“The positive FIBRONEER-ILD topline result shows the potential of nerandomilast in progressive pulmonary fibrosis,” Shashank Deshpande, Head of Human Pharma at Boehringer, said in the release. “The hope is that the safety and tolerability profile we are initially seeing could potentially help to reduce treatment challenges.”

TUESDAY, Jan. 14, 2025 -- Use of once-weekly semaglutide more than doubles the risk for nonarteritic anterior ischemic optic neuropathy (NAION) in individuals with type 2 diabetes , according to a study published online Dec. 18 in the International Journal of Retina and Vitreous . Jakob Grauslund, D.M.Sci., Ph.D., M.D., from Odense University Hospital in Denmark, and colleagues prospectively evaluated the use of semaglutide and risk for NAION in people with type 2 diabetes. The analysis included 424,152 individuals (2018 to 2024) exposed (106,454 individuals) or not exposed (317,698 individuals) to once-weekly semaglutide. The researchers found that semaglutide exposure was significantly associated with a higher incidence rate (0.228 versus 0.093 per 1,000 person-years) and independently predicted a higher risk for upcoming NAION (hazard ratio, 2.19), even when accounting for multiple other factors. Of the 67 persons exposed to semaglutide who developed NAION, there was a median time from first prescription to event of 22.2 months (interquartile range, 10.2 to 37.8 months). "During five years of observation of all persons with type 2 diabetes in Denmark, use of once-weekly semaglutide independently more than doubled the risk of NAION," the authors write. "Given the irreversible nature of NAION, it is important to acknowledge this risk, and upcoming studies should aim to identify high-risk subgroups." Abstract/Full Text Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.